Keywords
antifungal, antimicrobial resistance, artisanal cheeses, Candida, fluconazole
Yeasts are widely known for their application in food production, but also because of their clinical significance. As human pathogens, several species of yeasts, mainly of the genus Candida, are responsible for a great number of life-threatening infections. The occurrence of yeasts in cheeses, including pathogenic species, has been largely studied, yet the antifungal susceptibility of these microorganisms is rarely reported. Here, we identified the species and determined the antifungal susceptibility profile of 45 Candida isolates recovered from artisanal cheeses from 20 cities in Boyacá, Colombia. Among the species, Candida lambica (28.9%) prevailed, followed by Candida krusei (24.4%), Candida kefyr (22.2%), Candida lusitaniae (11.1%), Candida inconspicua (6.7%) Candida parapsilosis (4.4%) and Candida guillermondii (2.2%). Notably, all seven species have been globally reported, to a greater or lesser extent, to cause fungemia and other invasive infections with high mortality rates. Remarkably, most isolates of C. lambica C. krusei, C. inconspicua and C. parapsilosis were resistant to fluconazole, one of the most common drugs to treat candidiasis. Our findings highlight the importance of exploring the ecological niches of pathogenic yeasts, together with their antifungal susceptibility, considering that the emergence of resistance in non-commensal opportunistic pathogens poses a serious threat to public health.
antifungal, antimicrobial resistance, artisanal cheeses, Candida, fluconazole
The importance of yeasts is highlighted by their application in food production, as these fungi play a vital role in fermentation (Maicas 2020). However, the clinical significance of yeasts has also been clearly established, considering that these microorganisms, as human pathogens, are able to cause life-threatening infections, particularly among older patients and those with an underlying serious condition associated with medical interventions, comorbidities or immunosuppression (Firacative 2020). Moreover, as antifungal resistance emerges in several species of colonizing and environmental yeasts, management and treatment challenges for the infections that they cause also appear, which represents an even major problem to public health (Fisher et al. 2022). Among the most prominent disease-causing fungi are the ascomycetous yeasts of the genus Candida, which are responsible for the majority of cases of invasive fungal infection in hospital settings in the world, with some species having acquired or intrinsic resistance to commonly used antifungal drugs (Bongomin et al. 2017; Lamoth et al. 2018).
Given that several species of yeasts are frequently found not only in raw milk but also in surfaces and material related with cheese production, handling and manufacturing, the occurrence of these microorganisms in artisanal cheeses is broadly known (Minervini et al. 2001; Mounier et al. 2006). In addition, the implications of the presence of a particular species of yeasts in these dairy products have been widely investigated, since some species can positively contribute to the characteristic taste and flavour of cheeses, while other species can spoil the product, causing off-flavours, softening, and bad odours, among others undesirable signs of spoilage (Minervini et al. 2001; Suzzi et al. 2003; Fadda et al. 2004; Bintsis 2021). Interestingly, from the diverse assortment of yeast species that can be present in artisanal cheeses, not only species of Candida have been found, but also of the genera Geotrichum, Pichia, Rhodotorula, Saccharomyces and Trichosporon, which, albeit uncommon, are increasingly causing severe disease in humans (Bintsis 2021; Chen et al. 2021; Gil et al. 2023).
While the instances of invasive yeast infections potentially acquired from food exposure and consumption are infrequent, these may be progressively observed, given that several emerging pathogenic yeasts species are commonly recovered from various environmental sources, including food, rather than from the normal mycobiota of humans (Cooper Jr. 2010; Benedict et al. 2016). In Candida bloodstream infections (BSI), particularly, the gut has been suggested as the main source of endogenous acquisition, and although atypical Candida species are not usually part of the gastrointestinal mycobiota, these yeasts could be transient members of the gut, acquired during feeding (Nucci Marcio and Anaissie 2001; Auchtung et al. 2018).
As the number of patients at-risk for fungal infections increases, there is a concurrent dramatic upsurge in the number of known opportunistic fungal species that are able to cause disease. Therefore, studies like ours addressed to explore part of the wide diversity of ecological niches of human pathogenic yeasts are helpful to provide further insights into the distribution and expansion of these microorganisms. Moreover, to our knowledge, this is the first study establishing not only the occurrence but also the antifungal susceptibility of clinically relevant Candida species recovered from artisanal cheeses, with the identification of resistant isolates, mainly to fluconazole. Our study contributes to the little information regarding the epidemiology, ecology and antifungal susceptibility profiles of Candida lambica, Candida krusei, Candida kefyr, Candida lusitaniae, Candida inconspicua, Candida parapsilosis and Candida guillermondii, two of which are part of the recently issued World Health Organization (WHO) fungal priority pathogens list (WHO 2022).
Forty-five isolates of Candida species previously recovered from 29 artisanal cheeses in 20 cities in Boyacá, Colombia (Figure 1) and belonging to the Collection of Fungi and Microorganisms of Universidad de Boyacá (UBCHM), were studied. A unique isolate of Candida was recovered from 15 cheeses, while two different isolates were recovered from 12 cheeses and three different isolates from two cheeses. Isolates were identified by matrix-assisted laser desorption/ionization time-off-flight (MALDI-TOF) mass spectrometry using the MALDI Biotyper® (Bruker Daltonics Inc., Germany).
Isolates were kept at -80 °C in 2 ml of 10% ultra-pure glycerol (Thermo Fisher Scientific, catalogue number 15514011) and were cultured in Sabouraud dextrose agar (SDA) (BD DIFCO, catalogue number 210950) at 35 °C for 24 h prior to the experiments.
The colorimetric broth microdilution test, Sensititre® YeastOne® (Thermo Fisher Scientific, catalogue number YO9), was used to determine the susceptibility of the isolates to anidulafungin (AND), micafungin (MF), caspofungin (CAS), 5-fluorocytosine (FC), posaconazole (PZ), voriconazole (VOR), itraconazole (IZ), fluconazole (FZ) and amphotericin B (AB), which are lyophilized in each plate, following the manufacturer’s instructions. In brief, each isolate was grown on SDA for 24 h at 35 °C. Subsequently, a yeast inoculum was prepared, per isolate, in 5 ml of sterile water and adjusted to the 0.5 McFarland standard (1-5 × 106 cells/ml). From this cell suspension, 20 μl were mixed thoroughly with 11 ml of YeastOne® inoculum broth (Thermo Fisher Scientific, catalogue number Y3462) to obtain a final concentration of 1.8-9 × 103 cells/ml. From the last suspension, 100 μl were served into each well of a Sensititre® YeastOne® plate. Plates were sealed and incubated at 35 °C for 24 h. Minimum inhibitory concentration (MIC) values were defined as the lowest concentration of each antifungal that prevented the development of a pink or fuchsia colour, this is, the first blue well (no growth) for amphotericin B, or the first purple well (growth inhibition) or blue well (no growth) for echinocandins, 5-fluorocytosine and azoles (Espinel-Ingroff et al. 1999). The quality control strains of Candida krusei ATCC® 6258 and Candida parapsilosis ATCC® 22019 were used following the M27M44S guideline of the Clinical and Laboratory Standards Institute (CLSI) (CLSI 2022).
Susceptible or resistant isolates to certain antifungal drug were identified, when available, with the clinical breakpoints per species of Candida and per drug, as established by the CLSI and other studies on the antifungal susceptibility of rare yeasts (Borman et al. 2019; CLSI 2022). Per species of Candida with five or more isolates, and per antifungal drug, the frequency of MIC values was determined and the geometric mean MIC was calculated. Using the Mann–Whitney test, the differences in MIC values between species were established, per antifungal drug, with the software GraphPad Prism 9 (https://www.graphpad.com/, La Jolla, CA, USA). p-values <0.05 were considered statistically significant.
Among the 45 isolates included in this study, seven species of Candida were identified. From these, C. lambica (Pichia fermentans) was the most common species, with 13 (28.9%) isolates, followed by C. krusei (Pichia kudriavzevii) with 11 (24.4%), C. kefyr (Kluyveromyces marxianus) with 10 (22.2%), C. lusitaniae (Clavispora lusitaniae) with five (11.1%), C. inconspicua with three (6.7%), C. parapsilosis with two (4.4%) and C. guillermondii (Meyerozyma guilliermondii) with one (2.2%) isolate. From 10 cheeses with two isolates and the two cheeses with three isolates, two different species of Candida were identified. The occurrence of the species did not differ depending on the city.
Even though all seven species recovered from artisanal cheeses have been reported as human pathogens, C. parapsilosis, C. krusei and C. guillermondii are of major clinical relevance, as they are responsible for larger proportions of cases of candidemia and other forms of invasive candidiasis in different countries around the world (Table 1). To a lesser extent, C. lusitaniae, C. kefyr, C. inconspicua and C. lambica have been identified causing disease in humans.
Species | Teleomorph | n (%) | Ecology | Percentage |
---|---|---|---|---|
Candida lambica | Pichia fermentans | 13 (28.9%) | Widely distributed in nature and often found in foods and fruit juice, as well as being associated with humans and animals. | Infrequent |
Candida krusei1 | Pichia kudriavzevii | 11 (24.4%) | Widely distributed in nature often occurring in soil, on fruits and in various natural fermentations. | 2.5–2.7% |
Candida kefyr | Kluyveromyces marxianus | 10 (22.2%) | Mostly isolated from foods and beverages, especially dairy products, but also from decaying plant tissue and associated insects. | 0.16% |
Candida lusitaniae | Clavispora lusitaniae | 5 (11.1%) | The ecological niche is ill-defined. Recovered from necrotic cactus tissue and reported as the most abundant species in leaves from agave for tequila production. | 1.1% |
Candida inconspicua | None | 3 (6.7%) | A significant component of the yeast community in various cheeses. | 0.049% |
Candida parapsilosis2 | None | 2 (4.4%) | Poorly understood. The species has been recovered sporadically from a variety of substrates and localities. | 13–26.5%. |
Candida guillermondii | Meyerozyma guilliermondii | 1 (2.2%) | Widely distributed in nature. Recovered from insect frass, flowers, fruits and other food products. Opportunistic pathogen of animals. | 0.79–6.5% |
2 high priority in the World Health Organization fungal priority pathogens list (WHO 2022).
The majority of Candida isolates from this study were susceptible to the echinocandins tested, to most azoles and to amphotericin B, according to the CLSI breakpoints and other studies (Borman et al. 2019; CLSI 2022) (Table 2). However, 12 isolates (92.3%) of C. lambica, the most common species recovered, 10 (90.9%) of C. krusei, two (66.7%) of C. inconspicua and two (100%) of C. parapsilosis were resistant (R) to fluconazole (MIC ≥16 μg/ml) (Figure 1). In addition, the 10 fluconazole resistant isolates of C. krusei had concomitantly decreased susceptibility to 5-fluorocytosine (MIC ≥8 μg/ml). Intermediate susceptibility to 5-fluorocytosine (MIC = 16 μg/ml) was as well identified in one (10%) isolate of C. kefyr (Pfaller et al. 2002). Notably, fluconazole resistant isolates were identified in 16 (80%) of the 20 studied cities in Boyacá.
No. of isolates at MIC value (μg/ml)1 | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Antifungal2 | Species | n | GM3 | 0.0078 | 0.0156 | 0.0313 | 0.0625 | 0.125 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 |
AND | C. lambica | 13 | 0.02663 | 7 | 4 | 1 | 1 | |||||||||||
C. krusei | 11 | 0.04858 | 5 | 5 | 1 | |||||||||||||
C. kefyr | 10 | 0.03125 | 4 | 2 | 4 | |||||||||||||
C. lusitaniae | 5 | 0.05441 | 1 | 4 | ||||||||||||||
C. inconspicua | 3 | - | 3 | |||||||||||||||
C. parapsilosis | 2 | - | 1 | 1 | ||||||||||||||
C. guillermondii | 1 | - | 1 | |||||||||||||||
MF | C. lambica | 13 | 0.04303 | 1 | 7 | 4 | 1 | |||||||||||
C. krusei | 11 | 0.09715 | 1 | 4 | 4 | 2 | ||||||||||||
C. kefyr | 10 | 0.04123 | 1 | 7 | 1 | 1 | ||||||||||||
C. lusitaniae | 5 | 0.05441 | 1 | 4 | ||||||||||||||
C. inconspicua | 3 | - | 1 | 2 | ||||||||||||||
C. parapsilosis | 2 | - | 1 | 1 | ||||||||||||||
C. guillermondii | 1 | - | 1 | |||||||||||||||
CAS | C. lambica | 13 | 0.06953 | 4 | 4 | 4 | 1 | |||||||||||
C. krusei | 11 | 0.1943 | 1 | 2 | 8 | |||||||||||||
C. kefyr | 10 | 0.02062 | 1 | 5 | 3 | 1 | ||||||||||||
C. lusitaniae | 5 | 0.07179 | 4 | 1 | ||||||||||||||
C. inconspicua | 3 | - | 3 | |||||||||||||||
C. parapsilosis | 2 | - | 2 | |||||||||||||||
C. guillermondii | 1 | - | 1 | |||||||||||||||
FC | C. lambica | 13 | 0.5274 | 2 | 1 | 3 | 4 | 1 | 2 | |||||||||
C. krusei | 11 | 8 | 1 | 9 | 1 | |||||||||||||
C. kefyr | 10 | 0.134 | 7 | 1 | 1 | 1 | ||||||||||||
C. lusitaniae | 5 | 0.2872 | 3 | 1 | 1 | |||||||||||||
C. inconspicua | 3 | - | 1 | 1 | 1 | |||||||||||||
C. parapsilosis | 2 | - | 1 | 1 | ||||||||||||||
C. guillermondii | 1 | - | 1 | |||||||||||||||
PZ | C. lambica | 13 | 0.202 | 1 | 1 | 3 | 3 | 5 | ||||||||||
C. krusei | 11 | 0.151 | 1 | 5 | 4 | 1 | ||||||||||||
C. kefyr | 10 | 0.01675 | 3 | 3 | 4 | |||||||||||||
C. lusitaniae | 5 | 0.0136 | 2 | 2 | 1 | |||||||||||||
C. inconspicua | 3 | - | 1 | 2 | ||||||||||||||
C. parapsilosis | 2 | - | 2 | |||||||||||||||
C. guillermondii | 1 | - | 1 | |||||||||||||||
VOR | C. lambica | 13 | 0.2781 | 2 | 2 | 4 | 2 | 3 | ||||||||||
C. krusei | 11 | 0.3426 | 1 | 1 | 2 | 6 | 1 | |||||||||||
C. kefyr | 10 | 0.007813 | 10 | |||||||||||||||
C. lusitaniae | 5 | 0.001184 | 2 | 3 | ||||||||||||||
C. inconspicua | 3 | - | 2 | 1 | ||||||||||||||
C. parapsilosis | 2 | - | 2 | |||||||||||||||
C. guillermondii | 1 | - | 1 | |||||||||||||||
IZ | C. lambica | 13 | 0.101 | 1 | 1 | 3 | 4 | 4 | ||||||||||
C. krusei | 11 | 0.1331 | 1 | 2 | 3 | 4 | 1 | |||||||||||
C. kefyr | 10 | 0.02368 | 6 | 2 | 2 | |||||||||||||
C. lusitaniae | 5 | 0.03125 | 1 | 3 | 1 | |||||||||||||
C. inconspicua | 3 | - | 1 | 2 | ||||||||||||||
C. parapsilosis | 2 | - | 2 | |||||||||||||||
C. guillermondii | 1 | - | 1 | |||||||||||||||
FZ | C. lambica | 13 | 37.55 | 1 | 1 | 6 | 4 | 1 | ||||||||||
C. krusei | 11 | 26.49 | 1 | 2 | 5 | 3 | ||||||||||||
C. kefyr | 10 | 0.1539 | 7 | 3 | ||||||||||||||
C. lusitaniae | 5 | 0.3789 | 2 | 3 | ||||||||||||||
C. inconspicua | 3 | - | 1 | 1 | 1 | |||||||||||||
C. parapsilosis | 2 | - | 2 | |||||||||||||||
C. guillermondii | 1 | - | 1 | |||||||||||||||
AB | C. lambica | 13 | 0.1816 | 8 | 3 | 2 | ||||||||||||
C. krusei | 11 | 0.2663 | 6 | 2 | 3 | |||||||||||||
C. kefyr | 10 | 0.1768 | 8 | 1 | 1 | |||||||||||||
C. lusitaniae | 5 | 0.1436 | 4 | 1 | ||||||||||||||
C. inconspicua | 3 | - | 2 | 1 | ||||||||||||||
C. parapsilosis | 2 | - | 1 | 1 | ||||||||||||||
C. guillermondii | 1 | - | 1 |
When comparing the geometric mean MIC among C. lambica, C. krusei, C. kefyr and C. lusitaniae, per antifungal tested (Table 2), it was possible to establish that C. krusei was less susceptible to caspofungin, micafungin and 5-fluorocytosine than C. lambica, C. kefyr and C. lusitaniae (p < 0.05). Additionally, both C. lambica and C. krusei were less susceptible to anidulafungin and all azoles than C. kefyr and C. lusitaniae (p < 0.05). The susceptibility of the studied isolates to amphotericin B did not differ depending on these four species of Candida, with all studied isolates being susceptible to this polyene.
The identification of nonclinical reservoirs of human pathogenic yeasts is of upmost importance, since these might serve as a source of transmission and dissemination of invasive disease. In fact, the full contribution of the environmental reservoirs of Candida species to the well documented shifting epidemiology of candidiasis worldwide, remains largely uncharacterized (Lamoth et al. 2018). Here, we not only describe the occurrence of pathogenic Candida species from artisanal cheeses, but we also report the identification of about 60% of the isolates with resistance to fluconazole, some of them with concomitant reduced susceptibility to 5-fluorocytosine.
In our study, C. lambica was recovered in almost a third of samples, which is not surprising as this species was firstly isolated from butter milk in The Netherlands and since, it has been commonly encountered in different dairy products such as hard and white-brined cheeses as well as in fermented food (Kurtzman et al. 2011; Bintsis 2021). Even though there have been very few cases of human disease by C. lambica, this yeast has been able to cause fungemia, which is one of the most severe manifestations of invasive candidiasis, with high mortality rates (Pfaller and Diekema 2004; Vervaeke et al. 2008; Noni et al. 2020). Moreover, the resistance to fluconazole that characterises the isolates of this species, which agrees with our findings, could hinder treatment and lead to an inappropriate management, hence to a poor prognosis in patients with these infections (Borman et al. 2019).
C. krusei, which has emerged in the last years as a significant opportunistic pathogen affecting patients with hematologic malignancies and transplant recipients worldwide (Pfaller et al. 2008; Jamiu et al. 2021), was also commonly found in artisanal cheeses, as reported previously (Wanderley et al. 2013; Banjara et al. 2015). In Colombia, C. krusei is the fifth most common Candida species causing BSI, accounting for about 2.2% of all cases, as occurring worldwide (Pfaller and Diekema 2004; Cortes et al. 2020). Importantly, C. krusei has intrinsic resistance to fluconazole, as found in our isolates, reduced susceptibility to 5-fluorocytosine and is rapidly developing acquired resistance to other antifungal drugs, making it a multidrug-resistant pathogen, very difficult to treat (Pfaller et al. 2002; Pfaller et al. 2008).
Another emerging pathogen causing BSI in patients with blood cancer is C. kefyr (Reuter et al. 2005; Dufresne et al. 2014), which accounted for about 23% of isolates recovered from our artisanal cheeses. In a global study of candidemia, C. kefyr was the nineth most prevalent species of Candida, causing 0.16% of all cases (Pfaller and Diekema 2004), and its incidence was suggested to be influenced by exogenous exposure to yogurt and other milk products (Dufresne et al. 2014). Even though the ecology of this yeast is not fully understood, C. kefyr has been occasionally recovered from blue-veined cheeses and other dairy foods, as well as from fruits, plant material and even plastic devices (Kurtzman et al. 2011; Dufresne et al. 2014; Bintsis 2021). While resistance to antifungals is not common in C. kefyr, we report an isolate with intermediate susceptibility to 5-fluorocytosine, which emphasises the importance of monitoring the emergence of antifungal resistance in uncommon species (Pfaller et al. 2002).
Recovered from semi-hard, white brined and other cheeses, as well as from agave leaves (Wanderley et al. 2013; Bintsis 2021), C. lusitaniae was the fourth most common species recovered in our study. Known for its low susceptibility to fluconazole and amphotericin B, and its ability to acquire antifungal drug resistance within days of treatment, this Candida species has been recognized as a human pathogen for more than four decades (Scott et al. 2023; Angiolella et al. 2024). In fact, in a global surveillance, C. lusitaniae accounted for about 1.1% of all the cases of candidemia, affecting mainly immunocompromised patients with underlying malignancies (Pfaller and Diekema 2004).
Commonly recovered from lactic products, including milk, cheeses, or butter (Minervini et al. 2001; Suzzi et al. 2003; Bintsis 2021), C. inconspicua is a species that has been rarely recovered from clinical samples. Accounting for less than 0.05% of all cases of candidemia globally (Pfaller and Diekema 2004), this yeast, together with other rare yeast species, shared the traits of being the cause of invasive infections and having high MIC values to fluconazole and azole derivatives (Perez-Hansen et al. 2019), which difficult management.
While C. parapsilosis has been isolated from cheeses and milk products (Suzzi et al. 2003; Wanderley et al. 2013; Banjara et al. 2015; Fröhlich-Wyder et al. 2019), as reported herein, its relevance lies in the role of this species in healthcare. In Australia, Malaysia, and many countries of Europe and Latin America, including Colombia, C. parapsilosis is the second most important opportunistic pathogenic yeast, after Candida albicans, associated with intrahospital transmission, targeting neonates, immunosuppressed and patients with indwelling catheters (Pfaller and Diekema 2004; Nucci et al. 2013; Pappas et al. 2018; Arendrup et al. 2023; Hernández-Pabón et al. 2024). Remarkably, fluconazole and voriconazole cross-resistance has been described in C. parapsilosis, therefore, affected patients should be treated ideally with an echinocandin, which many times are unavailable in resource-limited countries (Cornely et al. 2012). Together with C. krusei, which was placed in the medium priority group, C. parapsilosis is in the high priority group of the WHO fungal priority pathogens list, highlighting the need to focus attention on the perceived public health importance of these species (WHO 2022).
C. guillermondii, which is most often associated with onychomycosis, is the fourth most frequent species causing invasive fungal infection in critically ill patients in Argentina, Honduras and Venezuela, fifth in Colombia (Nucci et al. 2013) and the seventh cause of BSI by Candida species globally (Pfaller and Diekema 2004). Unfortunately, resistance to amphotericin B, fluconazole and itraconazole, associated with treatment failure, and reduced susceptibility to several other classes of antifungals have been reported in C. guillermondii isolates (Pfaller et al. 2006). Although no specific clinical or environmental sources for infection have been identified, C. guillermondii may be transmitted from patient to patient in the hospital, particularly among those with intravascular foreign bodies (Pfaller et al. 2006).
The emergence of uncommon, yet resistant, pathogenic Candida species could be due to the selective pressure caused for a larger use of azole derivatives, particularly fluconazole, not only as antifungal prophylaxis but also as empirical therapeutics (Pfaller and Diekema 2004). Given its low cost and low toxicity, fluconazole remains one of the most commonly prescribed antifungal drugs against candidemia and candidiasis (Cornely et al. 2012). Moreover, the use of azoles as fungicides in agriculture, which can contribute to the appearance of antifungal-resistance in nature, is widely documented (CDC 2019).
The rise of species that are in addition resistant to other class of antifungals, including polyenes, flucytosine and echinocandins, makes these microorganisms multidrug-resistant, as it is the case of C. krusei, C. lusitaniae, and C. guillermondii, among the Candida species reported here, which further increases the risk for human health. Therefore, early detection, including the identification of environmental sources and exogenous exposure, as well as accurate species identification, are crucial to contribute to infection control. Our study provides important data on the occurrence of pathogenic Candida species recovered from artisanal cheeses and on the antifungal susceptibility of these, which until now is rather limited.
Underlying data is deposited in Figshare: Occurrence of pathogenic Candida species in artisanal cheeses from Boyacá, Colombia, including fluconazole resistant isolates. Doi: https://doi.org/10.6084/m9.figshare.26093389 (Sánchez-Quitian et al. 2024).
This project contains the following underlying data:
- Raw Data.xlsx (antifungal susceptibility testing (AST) data for each isolate and per species with characteristics of each isolate).
- Figure 1 (Map with the isolates).
Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).
The authors thank Claudia Parra from Unidad de Proteómica y Micosis Humanas, Grupo de Enfermedades Infecciosas, Departamento de Microbiología, Facultad de Ciencias, Pontificia Universidad Javeriana, for allowing the use of the MALDI-TOF. We also thank Óscar Perdomo, professor at Universidad de Boyacá, for his collaboration in the construction of the map.
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Is the work clearly and accurately presented and does it cite the current literature?
Partly
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
I cannot comment. A qualified statistician is required.
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Yes
References
1. Kidd SE, Abdolrasouli A, Hagen F: Fungal Nomenclature: Managing Change is the Name of the Game.Open Forum Infect Dis. 2023; 10 (1): ofac559 PubMed Abstract | Publisher Full TextCompeting Interests: No competing interests were disclosed.
Reviewer Expertise: Medical mycology
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Not applicable
Are all the source data underlying the results available to ensure full reproducibility?
No source data required
Are the conclusions drawn adequately supported by the results?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Medical microbiology, Mycology, Antimicrobial resistance, Host-pathogen interactions
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | ||
---|---|---|
1 | 2 | |
Version 3 (revision) 04 Oct 24 |
read | |
Version 2 (revision) 26 Sep 24 |
read | |
Version 1 11 Jul 24 |
read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)